Not all uncomfortable side effects for Depo-Provera Contraceptive Injection might be reported. You should always consult your doctor or physician for health advice.
In addition to its needed effects, some unwanted effects might be caused by medroxyprogesterone (the component contained in Depo-Provera). In the event that any of these uncomfortable side effects do occur, they might require medical help.
Cushing’s syndrome is uncommon and appears to get associated that has a long length of therapy and moderate to high doses of medroxyprogesterone (the ingredient contained in Depo-Provera) Doses used by hormonal replacement therapy as well as for long-term contraception usually are not associated with Cushing’s syndrome.
Medroxyprogesterone has mild glucocorticoid activity. In cases of medroxyprogesterone-induced Cushing’s syndrome, low cortisol and adrenocorticotrophic hormone (ACTH) levels having a reduced pituitary-adrenal reserve happen to be documented. Acute adrenal insufficiency may ensue following withdrawal of medroxyprogesterone.
Weight gain might be more frequently encountered than fat reduction during medroxyprogesterone (the active component contained in Depo-Provera) therapy. In women using intramuscular medroxyprogesterone for contraception, the mean putting on weight after 1 year of treatment therapy is 2.5 kg. After two, four, and six years, patients acquire a mean of 3.7, 6.3, and 7.5 kg, respectively.
Data with regards to the effect of medroxyprogesterone on lipid profiles happen to be conflicting. Some studies report possible uncomfortable side effects on lipid profiles although some have documented a decrease in total and low-density lipoprotein cholesterol plus an increase in high-density lipoprotein levels of cholesterol.
Genitourinary unwanted effects have been relatively common and included primarily menstrual changes for example amenorrhea, irregular bleeding, spotting, and high bleeding. Vaginal cysts, dyspareunia, and adjustments to cervical erosion and secretions seemed to be reported. While endometrial hyperplasia is reported, medroxyprogesterone (the ingredient contained in Depo-Provera) tended to experience a favorable impact on the endometrium. Changes in libido and anorgasmia also have occurred.
A significant improvement in the incidence of cancer of the breast in beagle dogs as well as an apparent boost in the incidence of endometrial cancer in rhesus monkeys was noted during the early animal carcinogenicity studies.
International long-term studies made to assess the likelihood of medroxyprogesterone (the active component contained in Depo-Provera) in humans, sponsored from the World Health Organization, neglected to find an increased chance cancer in users of medroxyprogesterone. Overall, there was clearly no significant surge in the risk of cancer of the breast, cervical cancer, or epithelial ovarian cancer. Data on the market studies did, however, support a tremendous (8-fold) decrease in the incidence of endometrial cancer among medroxyprogesterone users.
The most cases of thromboembolic disease during hormonal therapy have already been attributed to estrogens and never to progestins. However, it is demonstrated that medroxyprogesterone (the active component contained in Depo-Provera) a minimum of at high doses, can certainly create hypercoagulable state. Whether or not this plays a part in the development of thrombotic events remains unknown.
Because medroxyprogesterone might cause edema, it must be used cautiously in patients with underlying disease (like headaches, asthma, cardiovascular disease, renal dysfunction, or seizure disorders) which might be exacerbated by edema or fluid retention.